Data Management in Complex Clinical Trials: The Strategic Role of the FSP Model
13 minute read
Introduction
The pharmaceutical industry currently features a clinical research ecosystem characterized by unprecedented complexity. The convergence of decentralized trials, the use of real-world data, and the integration of eSource technologies have led to a significant increase in the volume, diversity, and fragmentation of clinical trial data. This increasing fragmentation of data sources has created challenges regarding data ownership and integration. As clinical trials evolve into multi-vendor ecosystems, ultimate responsibility effectively shifted back to the sponsor, who remains accountable for data quality and oversight despite distributed execution. Consequently, specifically within data management, the functional service provider (FSP) model emerges as a structurally effective strategy to address these challenges.
This dynamic model allows the sponsor to acquire specific external competencies without renouncing strategic direction. In this setup, the data manager operates as a functional extension of the pharmaceutical company’s internal team despite being contracted by the contract research organization (CRO), ensuring operational continuity and alignment with corporate objectives, while maintaining direct oversight of data standards, flows, and quality.
This white paper explores how sponsors can address the growing complexity of clinical trial data by repositioning data management as a strategic governance function. It outlines how the FSP model enables greater control, flexibility, and real-time visibility across multi-vendor environments, ultimately supporting faster, more confident decision-making and more efficient study execution.
Jump to a section:
Data Complexity and Sponsor Control
The current clinical research landscape is defined by a structural increase in data complexity that directly impacts how sponsors must govern, access, and use clinical data.
From Data Collection to Data Orchestration
Historically, clinical data management primarily focused on cleaning data captured in case report forms. This model is no longer sufficient; data volume has increased drastically and diversified significantly.
Data management now requires the orchestration of heterogeneous flows coming from very different sources, collecting data with diverse characteristics and structures. Clinical data is no longer site-centric but generated across a distributed digital ecosystem:
- ePRO and eCOA: Data reported directly by patients via mobile apps
- Devices, wearables, and sensors: Continuous flows generated by wearable devices monitoring subject parameters
- External data: Automatic imports from central laboratories and acquisition of complex diagnostic images
- Real-world data and electronic health records: Increasingly deep integration with electronic health records for the use of real-world data
As a result, no single vendor has end-to-end visibility of the data, making fragmented oversight a structural risk and requiring centralized governance at the sponsor level. This shift fundamentally redefines data management as a data integration and governance function, rather than a data cleaning activity. The data manager role therefore evolves from an “operational/manual” role to a “strategic/technological” one, becoming the central reference point for numerous processes and systems.
Real-time Visibility and Sponsor Oversight
In parallel, risk-based quality management has established real-time data oversight as a requirement rather than an option. Sponsors must now take decisions in real-time during the study. Periodic reporting and retrospective data review are insufficient to ensure control in this environment, particularly given that regulatory standards (e.g., CDISC, SDTM, CDASH) require consistency and compliance from the earliest stages of study design.
In this context, the ability to maintain continuous visibility and control over data is determined by more than operational execution alone and now includes the underlying governance model adopted by the sponsor.
Sourcing Models and Data Governance
The explosion of data sources and the complexity of their integration require a holistic view. Traditional resourcing approaches are no longer sufficient, as data management now requires the orchestration of an ecosystem of interconnected data with continuous oversight and control. In this context, the choice of sourcing model is no longer a purely operational decision, but a strategic lever that directly determines a sponsor’s ability to maintain data visibility, ensure quality, and support real-time decision-making.
Variable data volumes and the demand for specific, evolving skills lead to sourcing strategies that prioritize agility and continuity of data governance. The current sourcing landscape can be broadly structured into four main operating models, each with distinct implications for control, visibility, and long-term data strategy:
- In-house model (internalization): full control through internal teams
- Full service outsourcing (FSO): full delegation of execution to a CRO
- FSP: external expertise embedded within sponsor systems and governance
- Hybrid models: strategic combination of FSP and FSO based on function criticality
In-House Model (Internalization)
The In-House Model represents the historic approach where the sponsor maintains total control over the study and various activities. This model provides maximum direct oversight of data, systems, and processes.
- Characteristics: team is composed entirely of direct employees operating on the sponsor’s systems
- Pros: guarantees maximum control over quality and know-how retention, as well as full visibility of data throughout the study lifecycle
- Cons: entails high fixed costs and difficulty in scaling rapidly based on workload peaks and often proves unsustainable due to the variability of modern trials and their extreme complexity
Full-Service Outsourcing (FSO—”Turnkey”)
This has been the standard response to the need for operational capacity for years and remains a valid and widespread model. It is primarily designed to optimize execution efficiency rather than sponsor-side governance and control.
- Characteristics: sponsor entrusts the entire study to a CRO, which uses its own standard operating procedures (SOPs) and systems
- Pros: simplifies contractual management but relies on a model originally designed for single-partner delivery environments
- Cons: can be limiting in today’s complex trial environment to the sponsor’s immediate visibility on data and direct control of the database until study closure; changing CROs entails loss of historical knowledge related to data structures, standards, and study-specific decisions
Functional Service Provider (FSP—Integration)
FSP represents a model designed to combine external expertise with sponsor-side governance, control, and continuity.
- Characteristics: CRO provides dedicated resources that work on the sponsor’s systems and according to the sponsor’s SOPs, integrating into corporate flows
- Pros: sponsor maintains control over data and processes and enjoys the flexibility of external resources, enabling continuous visibility into data, alignment with internal standards, and more effective support for real-time decision-making across studies
Hybrid Models (Mixed Models)
Many pharmaceutical companies today use the FSP model for “core” and sensitive functions (e.g., data management) to maintain control over data, while entrusting more operational and logistic activities (e.g., site monitoring, data cleaning, coding) to FSO. This guarantees that sponsors can re-establish internal governance while outsourcing execution. As a result, FSP becomes a central component in sustaining long-term data strategy and organizational knowledge.
Fragmented Accountability Versus Integrated Governance in Clinical Data Management
In contemporary outsourcing models, the core challenge for clinical data and operations leaders is not simply transparency between sponsor and CRO, but the distribution of accountability across different systems, infrastructures, and operational standards. When data ownership, system control, and process governance are structurally separated, fragmentation may emerge even in the presence of good collaboration.
The comparison below highlights how FSO and FSP models directly impact data consistency, operational efficiency, and the sponsor’s ability to support real-time decision-making.
FSO: Distributed Accountability Across External Systems
Under the FSO model, the sponsor delegates full trial execution to a CRO, which typically designs and manages the database. Although operational delivery may be efficient, system ownership and configuration remain external to the sponsor’s environment. Accountability for data standards, validation rules, and system governance is therefore embedded within the CRO’s framework and the sponsor often only sees the definitive data during statistical analysis and final transfer, creating information asymmetry. Furthermore, across multiple studies, different CRO partnerships may introduce variations in data structures, conventions, and workflows. Even when transparency is maintained, this structural dispersion can increase complexity in cross-study harmonization, integrated analyses, and long-term data strategy alignment.
FSP: Integrated Governance Within the Sponsor’s Ecosystem
In the FSP model, the data manager works on the sponsor’s systems and has real-time access to study data, enabling continuous oversight. Accountability for data standards, system configuration, and quality oversight remain centralized within the sponsor’s infrastructure, even when operational resources are externally sourced. This integrated model reduces structural fragmentation, promotes consistency across programs, and supports long-term standardization strategies. While improved visibility is a direct outcome, the primary benefit lies in enabling continuous control over data quality and supporting faster, more confident decision-making in complex trial environments.
Strategic comparison: selecting the appropriate operating structure
Each model offers distinct advantages depending on organizational priorities and strategic objectives.
How the FSP Model Enables Control, Quality, and Real-Time Decision-Making
The FSP model is designed to embed data management capabilities within the sponsor’s governance framework, enabling direct control over data, standards, and decision-making while leveraging external expertise.
A complex relational triangle is created:
- Sponsor: defines strategic objectives and priorities, and approves the deliverables
- CRO: provides the methodological framework, training, and compliance, and manages human resources aspects
- FSP data manager: acts as the strategic bridge and central coordination role between the sponsor’s vision and the CRO’s execution; operates as a functional extension of the internal team, orchestrates data standards across multiple vendors, translates complex clinical needs into technical specifications, and provides qualified technical oversight to ensure real-time alignment and risk mitigation
As a result, the FSP model enables sponsors to:
- maintain direct control and visibility over clinical data across vendors.
- apply consistent data standards and governance frameworks across studies.
- retain critical knowledge within the organization.
- establish continuous oversight and early issue detection mechanisms.
- support real-time access to reliable data during study execution.
Data Custody and Knowledge Retention
One of the critical risks of traditional outsourcing is the loss of knowledge retention for a specific compound if the sponsor changes the CRO after a study concludes. The FSP data managers build a strong “historical memory” regarding the sponsor’s specific therapeutic areas, compound peculiarities, and internal operational preferences. They also continuously refresh their industry knowledge and systematically introduce external best practices. This enables them to offer objective, strategic guidance to the pharmaceutical company, rather than becoming constrained by a single operational environment. This unique combination of broad external insight and deep internal “institutional knowledge” can significantly reduce setup times for new studies and improve the management of study activities.
Technical Oversight of the CROs
In a hybrid model specifically, one of the most important value contributions of the FSP data manager is the ability to exercise qualified technical oversight over the work of CROs managing the study in full-service. With increasing specialization in modern trials, sponsors may lack the internal expertise required to effectively assess the quality of CRO deliverables and vendor outputs in real time. This oversight extends beyond deliverables to include strict evaluation of how activities are performed, ensuring compliance with sponsor standards and SOPs. The FSP data manager, usually a figure with high seniority and multiyear experience, bridges this gap by acting as a proactive “Technical Lead,” ensuring quality by design. By operating at the same technical level as CRO teams, they reduce misunderstandings and minimize correction cycles. This level of integration enables early detection of design and integration issues, reducing risk and accelerating database lock and study timelines.
This oversight applies across all critical study phases, including:
- case report form review: ensures data design reflects the protocol without redundancies that would slow down sites, while ensuring consistency across different studies through application of sponsor standards
- data validation plan: verifies that automatic checks are logical and effective across forms, also proposes improvements or measures the development CRO might not be used to utilizing (e.g., automatic emails, complex listing reviews, etc.)
- user acceptance testing: performs rigorous testing on the database and edit checks before the GoLive, an activity requiring time and a “clinical eye” that the sponsor can rarely allocate internally
- technical management (data transfer specifications and issue tracker): validates the study design and verifies vendor implementation from the outset; ensures potential issues are detected and resolved early in the study lifecycle, mitigating risks associated with data integration and transfer
Having an FSP expert aligned with CRO technical teams reduces misunderstandings, minimizes rework, and ensures data quality is built by design, accelerating study closure timelines.
The FSP data manager acts as the central coordination layer:
- Inwards: translates the needs of the sponsor’s various departments (e.g., project manager, medical expert, pharmacovigilance)
- Outwards: orchestrates vendors (e.g. laboratories, clinical CRO, electronic data capture system providers, biometrics CRO), ensuring data flows correctly between different systems without integrity loss and respecting timelines
These capabilities translate into measurable improvements in data quality, operational efficiency, and decision-making, as outlined in the following section.
Impact on Data Quality, Efficiency, and Decision-making
Operational Consistency and Decision Confidence
In complex clinical programs involving multiple vendors, inconsistent data interpretation can introduce variability, delays, and operational risk. The FSP model ensures standardized processes, aligned quality frameworks, and centralized oversight across activities, reducing ambiguity, and ensuring uniform data handling. This consistency enhances data reliability and strengthens the sponsor’s confidence in the strategic and clinical decision-making process.
By enabling continuous access to reliable data and maintaining direct oversight, the FSP model also supports faster identification of issues and more proactive decision-making during study execution.
Flexibility and Cost Efficiency
Workload in data management is not always linear and constant over time. The FSP model allows the sponsor to modulate resources dynamically based on actual operational demands and fluctuating workloads, avoiding the fixed costs of internal personnel during quieter periods. FSP involvement is completely tailored; sponsors can rapidly scale resources during critical phases (e.g., study build, database lock) and reduce capacity during lower-activity periods. This highly adaptable approach ensures cost efficiency by aligning expert capacity directly with real-time project needs.
Access to Skills and Innovation
To remain competitive and manage increasing data complexity, CROs are making heavy investments in advanced technology stacks (e.g., artificial intelligence (AI), data visualization) and workforce upskilling. The FSP model allows the sponsor to benefit from these investments by receiving highly qualified professionals already updated on best practices without bearing direct costs. This enables sponsors to access specialized expertise and evolving best practices without long-term investment in internal capability building.
Conclusion
The FSP model is not static but continues to evolve alongside advances in clinical data technologies. The next phase of this evolution will be driven by the increasing integration of AI into clinical data processes. However, as automated processing increases, strict adherence to evolving regulatory guidelines and a human-in-the-loop governance role becomes more critical.
This shift further elevates the data manager’s role from technical operator to a Strategic Governance Lead, responsible for managing data flows, risk-based quality management, and data-driven decision-making. In parallel, the ever-increasing complexity of clinical studies will favor the emergence of FSP data managers highly specialized in the technical management of unconventional data flows, such as those from wearables, biometric sensors, and real-world data. Data management will increasingly require real-time orchestration of heterogeneous data flows rather than retrospective data handling.
Market dynamics suggest a transitional phase; as pharmaceutical companies integrate AI and optimize internal structures, reliance on targeted FSP partnerships is expected to increase to maintain governance, expertise, and operational continuity while new technologies are validated within clinical and regulatory frameworks.
For clinical data and operations leaders managing increasingly complex trials, the ability to maintain control over data quality and support real-time decision-making has become a critical success factor. Traditional outsourcing models, while effective for execution, often limit visibility and fragment accountability across systems and partners.
The FSP model addresses these limitations by embedding data management capabilities within the sponsor’s governance framework, enabling continuous oversight, consistent data standards, and more efficient study execution.
As a result, data management evolves from an operational function to a strategic capability, supporting faster decision-making, reduced risk, and improved performance across clinical programs.
References:
- Kelly Science & Clinical Case Study: “Reducing costs and increasing value for a global pharmaceutical company”.
- GForce Life Sciences: “What is the FSP Model in Clinical Research?”
- ISR Reports, “Clinical Development Outsourcing Models” (Analysis on FSP adoption trends).
Author:
Ivan Migliori,
Principal Data Manager
Author:
Ivan Migliori,
Principal Data Manager
Subscribe to our newsletter for the latest news, events, and thought leadership